Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase II Study of Sorafenib in Combination With Erlotinib in Non-small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens
Conditions
Interventions
erlotinib hydrochloride
sorafenib tosylate
+7 more
Locations
1
South Korea
Yonsei Cancer Center at Yonsei University Medical Center
Seoul, South Korea
Start Date
September 1, 2008
Primary Completion Date
June 1, 2009
Last Updated
August 25, 2009
NCT07190248
NCT05692635
NCT07485114
NCT07486219
NCT07336732
NCT06066138
Lead Sponsor
Yonsei University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions